- Home
- HCM vs IDYA Comparison
HCM vs IDYA Comparison
Compare HCM & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCM | IDYA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HCM | IDYA |
|---|---|---|
| Price | $13.35 | $35.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $13.75 | ★ $49.42 |
| AVG Volume (30 Days) | 21.1K | ★ 1.0M |
| Earning Date | 08-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $602,197,000.00 | $214,834,000.00 |
| Revenue This Year | N/A | $2,434.86 |
| Revenue Next Year | $15.54 | N/A |
| P/E Ratio | $4.90 | ★ N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | $11.51 | $13.45 |
| 52 Week High | $19.50 | $37.08 |
Technical Indicators
Market Signals| Indicator | HCM | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 30.04 | 61.26 |
| Support Level | $13.06 | $33.11 |
| Resistance Level | $13.59 | $34.45 |
| Average True Range (ATR) | 0.24 | 1.43 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 11.13 | 60.43 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.